NovaBay Pharmaceuticals, Inc.
NBY
$0.58
-$0.02-3.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 26.34% | 11.99% | 9.16% | 9.13% | -436.64% |
| Total Depreciation and Amortization | -12.50% | -17.65% | -17.33% | -35.61% | -14.09% |
| Total Amortization of Deferred Charges | 28.87% | 328.67% | -- | -- | -- |
| Total Other Non-Cash Items | -41.24% | -10.82% | -9.34% | 25.70% | 197.47% |
| Change in Net Operating Assets | -149.83% | 350.70% | -134.37% | -134.90% | 168.09% |
| Cash from Operations | 5.89% | 52.24% | 30.75% | 37.90% | 48.51% |
| Capital Expenditure | 50.00% | 92.63% | 93.07% | 83.93% | 86.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 6,737.50% | 1,218.95% | 1,152.48% | 83.93% | 99.87% |
| Total Debt Issued | -100.00% | -100.00% | -- | -- | 2,757.14% |
| Total Debt Repaid | -249.87% | -1,185.49% | -- | -1,303.81% | -633.33% |
| Issuance of Common Stock | -- | -53.55% | -66.82% | -66.82% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -79.64% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.32% | 99.32% | -- | -- | -- |
| Cash from Financing | -80.41% | -123.33% | -72.29% | -58.77% | -69.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -1,631.25% | -- | -- | -- |
| Net Change in Cash | -638.36% | -600.00% | -41.06% | -18.75% | 93.34% |
